News Medical | Shreeya Nanda
In solid-organ transplant recipients (OTRs) diagnosed with cancer post-transplant, treatment with sirolimus reduces the risk of developing a subsequent skin cancer, US investigators report in JAMA Dermatology.
They reviewed the electronic medical records of 329 patients who developed cancer a median of 42 months after undergoing solid-organ transplantation. Of these, 29.5% received the mammalian target of rapamycin (mTOR) inhibitor after diagnosis of the index cancer, while the remaining 70.5% did not.
Overall, 39.5% of study participants were diagnosed with a second post-transplant malignancy, at a median of 14 months after the index cancer, with the majority (88.5%) developing skin cancer, a known risk for OTRs.
A significantly smaller proportion of sirolimus-treated patients than those not treated developed a second post-transplant cancer, at 30.9% versus 43.1%, equating to a 12.2% decrease in the risk of a subsequent cancer of any type. Continue reading